VU Research Portal
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
in Non-Small Cell Lung Cancer
Kuiper, J.L.
2016
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Kuiper, J. L. (2016). Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Acquired Resistance to Epidermal Growth
Factor Receptor Tyrosine Kinase Inhibitors in
Non-Small Cell Lung Cancer
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Justine Leonie Kuiper
Thesis, Faculty of Medicine, VU University medical center, VU University, The Netherlands
ISBN: 978-94-6233-440-3 Author: Justine Leonie Kuiper
Cover illustration: Nicole Nijhuis - Gildeprint Lay-out and printing: Gildeprint, Enschede Copyright © J.L. Kuiper, the Netherlands, 2016
All rights reserved. No parts of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without written permission from the author or from the Publisher holding the copyright of the published articles.
Publication of this thesis was financially supported by:
Boehringer Ingelheim B.V., Vrije Universiteit Amsterdam, Chipsoft, AstraZeneca
VRIJE UNIVERSITEIT
Acquired Resistance to Epidermal Growth
Factor Receptor Tyrosine Kinase Inhibitors in
Non-Small Cell Lung Cancer
ACADEMISCH PROEFSCHRIFT
ter verkrijging van de graad Doctor aan de Vrije Universiteit Amsterdam, op gezag van de rector magnificus
prof.dr. V. Subramaniam, in het openbaar te verdedigen ten overstaan van de promotiecommissie
van de Faculteit der Geneeskunde op donderdag 8 december 2016 om 9.45 uur
in de aula van de universiteit, De Boelelaan 1105
door
Justine Leonie Kuiper
CONTENT
Introduction
Ch. 1: Introduction and outline of this thesis 9
Diagnostics & response prediction
Ch. 2: Non-classic EGFR-mutations in a cohort of Dutch EGFR-mutated 29 NSCLC-patients and outcomes following EGFR-TKI treatment
Accepted for publication in British Journal of Cancer
Ch. 3: Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated 51 NSCLC-patients
Lung Cancer 2014 Jul;85(1):19-24
Ch. 4: Ch. 4a: Detecting resistance in EGFR-mutated NSCLC after clonal selection 69 through targeted therapy
Personalized Medicine 2015 Apr;12(2): 63-6
Ch. 4b: Transformation to a squamous cell carcinoma phenotype of an 75 EGFR-mutated NSCLC-patient after treatment with an EGFR-tyrosine
kinase inhibitor
Journal of Clinical Pathology 2015 Apr;68(4):320-1
Ch. 5: VeriStrat® has prognostic value in advanced stage NSCLC-patients treated 81 with erlotinib and sorafenib
British Journal of Cancer 2012 Nov 20;107(11):1820-5
Treatment
Ch. 6: Challenges in the management of EGFR-mutated non-small cell lung 97 cancer patients with acquired resistance to tyrosine kinase inhibitors
Oncology 2014;87(2):83-94
Ch. 7: Treatment and survival of patients with EGFR-mutated non-small cell lung 115 cancer and leptomeningeal metastasis: A retrospective cohort analysis
Lung Cancer 2015 Sep;89(3):255-61
Ch. 8: Ch. 8a: High-dose, pulsatile erlotinib in two NSCLC-patients with 131 leptomeningeal metastases – one with a remarkable thoracic response
as well
Lung Cancer 2013 Apr;80(1):102-5
Ch. 8b: High-dose, weekly erlotinib is not an effective treatment in 139 EGFR-mutated non-small cell lung cancer patients with acquired
extracranial progressive disease on standard dose erlotinib
Ch. 9: Outcome on afatinib in NSCLC-patients who progressed on prior treatment 153 with erlotinib or gefitinib
In progress
Discussion
Ch. 10: Ch. 10a: Summary and future perspectives 165 Ch. 10b: Dutch summary (Nederlandse samenvatting) 177
Curriculum Vitae 187
Dankwoord 189
